Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
INTRODUCTION

Coronavirus Disease-2019 (COVID-19) has profoundly affected the United States (US) health care system. Given the novelty of the disease, there is tremendous uncertainty about the potential impact on transplant candidates and recipients. Early in the pandemic, transplant centers and patients had reservations about the reliable detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Using SRTR data, we compared observed LT waitlist registrations, waitlist mortality, deceased donor LTs (DDLT), and living donor LTs (LDLT) 3/15/2020-8/31/2020 to expected values based on historical trends 1/2016-1/2020, stratified by statewide COVID-19 incidence. Overall, from 3/15 to 4/30, new listings were 11% fewer than expected (IRR = 0.84 [0.89-0.93]), LDLTs were 49% fewer (IRR = 0.37 [0.51-0.72]), and DDLTs were 9% fewer (IRR = 0.85 [0.91-0.97]). In May, new listings were 21% fewer (IRR = 0.74 [0.79-0.84]), LDLTs were 42% fewer (IRR = 0.39 [0.58-0.85]), and DDLTs were 13% more (IRR = 1.07 [1.15-1.23]). Centers in states with the highest incidence 3/15-4/30 had 59% more waitlist deaths (IRR = 1.09 [1.59-2.32]) and 34% fewer DDLTs (IRR = 0.50 [0.66-0.83]). By August, waitlist outcomes were occurring at expected rates, except for DDLT (13% more across all incidences). While the early COVID-affected states endured major transplant practice changes, later in the pandemic the newly COVID-affected areas were not impacted to the same extent. These results speak to the adaptability of the transplant community in addressing the pandemic and applying new knowledge to patient care.

KEYWORDS
clinical research/practice, health services and outcomes research, liver disease, liver transplantation/hepatology, waitlist management

1 INTRODUCTION

Coronavirus Disease-2019 (COVID-19) has profoundly affected the United States (US) health care system. Given the novelty of the disease, there is tremendous uncertainty about the potential impact on transplant candidates and recipients. Early in the pandemic, transplant centers and patients had reservations about the reliable detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Using SRTR data, we compared observed LT waitlist registrations, waitlist mortality, deceased donor LTs (DDLT), and living donor LTs (LDLT) 3/15/2020-8/31/2020 to expected values based on historical trends 1/2016-1/2020, stratified by statewide COVID-19 incidence. Overall, from 3/15 to 4/30, new listings were 11% fewer than expected (IRR = 0.84 [0.89-0.93]), LDLTs were 49% fewer (IRR = 0.37 [0.51-0.72]), and DDLTs were 9% fewer (IRR = 0.85 [0.91-0.97]). In May, new listings were 21% fewer (IRR = 0.74 [0.79-0.84]), LDLTs were 42% fewer (IRR = 0.39 [0.58-0.85]), and DDLTs were 13% more (IRR = 1.07 [1.15-1.23]). Centers in states with the highest incidence 3/15-4/30 had 59% more waitlist deaths (IRR = 1.09 [1.59-2.32]) and 34% fewer DDLTs (IRR = 0.50 [0.66-0.83]). By August, waitlist outcomes were occurring at expected rates, except for DDLT (13% more across all incidences). While the early COVID-affected states endured major transplant practice changes, later in the pandemic the newly COVID-affected areas were not impacted to the same extent. These results speak to the adaptability of the transplant community in addressing the pandemic and applying new knowledge to patient care.

KEYWORDS
clinical research/practice, health services and outcomes research, liver disease, liver transplantation/hepatology, waitlist management

1 INTRODUCTION

Coronavirus Disease-2019 (COVID-19) has profoundly affected the United States (US) health care system. Given the novelty of the disease, there is tremendous uncertainty about the potential impact on transplant candidates and recipients. Early in the pandemic, transplant centers and patients had reservations about the reliable detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Using SRTR data, we compared observed LT waitlist registrations, waitlist mortality, deceased donor LTs (DDLT), and living donor LTs (LDLT) 3/15/2020-8/31/2020 to expected values based on historical trends 1/2016-1/2020, stratified by statewide COVID-19 incidence. Overall, from 3/15 to 4/30, new listings were 11% fewer than expected (IRR = 0.84 [0.89-0.93]), LDLTs were 49% fewer (IRR = 0.37 [0.51-0.72]), and DDLTs were 9% fewer (IRR = 0.85 [0.91-0.97]). In May, new listings were 21% fewer (IRR = 0.74 [0.79-0.84]), LDLTs were 42% fewer (IRR = 0.39 [0.58-0.85]), and DDLTs were 13% more (IRR = 1.07 [1.15-1.23]). Centers in states with the highest incidence 3/15-4/30 had 59% more waitlist deaths (IRR = 1.09 [1.59-2.32]) and 34% fewer DDLTs (IRR = 0.50 [0.66-0.83]). By August, waitlist outcomes were occurring at expected rates, except for DDLT (13% more across all incidences). While the early COVID-affected states endured major transplant practice changes, later in the pandemic the newly COVID-affected areas were not impacted to the same extent. These results speak to the adaptability of the transplant community in addressing the pandemic and applying new knowledge to patient care.
(SARS-CoV-2) in candidates, recipients, and donors.\textsuperscript{5,6} Furthermore, due to the rapidly evolving knowledge about management and prognosis for patients with COVID-19,\textsuperscript{7} there were no evidence-based guidelines for management pre- and posttransplant.\textsuperscript{5,6,8-11} Because of these uncertainties, transplant centers have been cautious to hospitalize, operate, and immunosuppress patients in the setting of COVID-19.\textsuperscript{12}

These uncertainties along with considerable increases in COVID-19-related hospitalizations and deaths\textsuperscript{1} may have impacted liver transplant (LT) across the US. A national survey between March 24 and 31, 2020, found 67.7% of LT centers had stopped performing live donor LT (LDLT).\textsuperscript{12} Although 73.3% of centers reported some restrictions for deceased donor LT (DDLT),\textsuperscript{12} there was substantial heterogeneity in the criteria used to determine transplant restrictions and minimal use of treatment protocols. Furthermore, COVID-19 disease burden varies by state,\textsuperscript{13,14} which may differentially impact transplant center behavior, but data-driven inference about the center-level changes and their correlation of geographic disease burden has not been characterized.

To address this knowledge gap, we used data from Scientific Registry of Transplant Recipients (SRTR) to retrospectively quantify changes to LT waitlist registration, waitlist mortality, and LT rates March-August, 2020. We further investigated these outcomes based on transplant candidate characteristics and local COVID-19 incidence, with the goal of providing insight about early pandemic changes in LT.

2 | METHODS

2.1 | Data source

This study used data from the Scientific Registry of Transplant Recipients (SRTR). The SRTR data system includes data on all donor, waitlisted candidates, and transplant recipients in the United States, submitted by the members of the Organ Procurement and Transplantation Network (OPTN). The Health Resources and Services Administration (HRSA), US Department of Health and Human Services provides oversight to the activities of the OPTN and SRTR contractors. The SRTR data system has previously been described elsewhere.\textsuperscript{15}

2.2 | State-level COVID-19 incidence

We determined the incidence of COVID-19 cases per 100,000 per day for each state (including the District of Columbia and Puerto Rico) over five 1-week periods in 2020. Outcomes from 3/15 to 4/30 were stratified based on state-level per-capita COVID-19 incidence in the last week of March. Outcomes from each month of May through August were stratified based on per-capita COVID-19 incidence during the last week of the prior month. We used publicly available data to evaluate the relationship between COVID-19 disease burden and LT waitlist events.\textsuperscript{13,14} Each state in each time period was stratified based on the incidence into “low” (0-3 cases/100,000/day), “medium” (4-7 cases/100,000/day), “high” (8-11 cases/100,000/day), and “very high” (>11 cases/100,000/day).

2.3 | Daily counts of LT waitlist events

To characterize national changes to the liver waitlist over time, we plotted daily counts of waitlist events between February 1 and September 2, 2020 with a LOWESS smooth curve. Waitlist events included new waitlist registrations, newly inactive registrants, and waitlist removals due to DDLT, LDLT, death, or deteriorating condition. For new registrations, changes to inactive status, and LDLT, only weekday counts were included since >97.5% of these events between 2016 and 2019 fell on weekdays. We made similar plots of daily counts for DDLT, donation after circulatory death (DCD), regional import DDLT, and national import DDLT. Due to the sudden decrease in LDLT after March 15, we plotted center-level counts of LDLT between March 15 and September 2, 2020 by state-level COVID-19 cases per 100,000 per day.

2.4 | Calculating center-level expected numbers of LT waitlist events

To determine the expected number for each waitlist event for comparison to observed counts, we used data from each center by month from February 1, 2016 to January 31, 2020. Using multilevel Poisson regression with a center-level random intercept, we modeled the number of outcomes per center per month. We adjusted at the center-level for distributions of candidate characteristics at the start of each month: age, sex, prior transplant, race/ethnicity, history of diabetes, insurance type, Model of End-stage Liver Disease (MELD), and ABO blood type. We used these models to predict the expected number of monthly waitlist events in 3/15-4/30/2020, May, June, July, August, overall, and for subgroups of patients based on candidate characteristics.

2.5 | Comparing observed to expected center-level numbers of LT waitlist events

We used the Pearson's chi-square test to compare the observed to expected frequencies for each waitlist event. Furthermore, we used Poisson regression to compare the observed versus expected events among centers in states with different levels of COVID-19 burden. We did this by modeling the observed counts, including the log of the expected counts with the coefficient constrained to 1, and adjusted for state-level COVID-19 burden. The incidence rate ratios (IRRs) represent the observed counts as a proportion of expected counts.
2.6 | Statistical analysis

All p-values are two-sided with an alpha of 0.05. Confidence intervals are reported as per the method of Louis and Zeger. All analyses were performed using Stata 16.1/MP for Linux (College Station, TX).

3 | RESULTS

3.1 | State-level COVID-19 incidence

During the last week of March, 2020 (3/25-3/31), there were 39 states with “low” COVID-19 incidence (as described above), 7 states with “medium” incidence, 3 states with “high” incidence, and 3 states with “very high” incidence (Figure 1). The states with “very high” incidence were New York, New Jersey, and Michigan. During the last week of April (4/24-4/30), the states with “very high” incidence were New York, New Jersey, Rhode Island, Massachusetts, Delaware, Washington, D.C., Connecticut, Illinois, Maryland, Iowa, and Nebraska. During the last week of May (5/25-5/31), the states with “very high” incidence were Washington, D.C., Maryland, Iowa, and Nebraska. During the last week of June (6/24-6/30), states were almost evenly distributed among the four incidence categories. During the last week of July (7/25-7/31), the distribution of states in the “very high” and “very low” incidence groups had reversed with “very low” consisting of only Vermont, Maine, New Hampshire, and New York, and the majority of states in the “very high” category.

3.2 | Daily counts of LT waitlist events

From February 1 to March 15, 2020, the average number of new waitlist registrants was 54.3 per weekday (Figure 2A). Subsequently, the average number of new waitlist registrants dropped to 44.6 per weekday during March 16-May 3 and then increased. The number of patients newly inactivated remained stable from February 1 to September 2 except for 5 days in the second half of March that were higher than average (Figure 2B). An outlier value on March 25, 2020 was caused by a center in a “very high” COVID-19 burden state inactivating its entire waitlist on that date. The percentage of inactive patients remained stable during April-September (Figure 2C).

From February 1 to September 2, the number of patients removed from the waitlist due to death averaged 2.8 per day (Figure 3A). The upward and downward trends at either end of the LOWESS curves are a typical statistical aspect of the smoothing process and may not represent a meaningful change. The number of patients removed from the waitlist due to deteriorating condition averaged 3.8 per day from February 1 to March 15. There was a downward trend mid-March to mid-April and an upward trend to baseline from mid-April to September (Figure 3B). The number of DDLTs decreased from an average of 25.1 per day from February 1-March 15 to a nadir on April 5 (Figure 4A). Afterwards, DDLT increased to baseline and plateaued from April to September. From February 1 to September 2, the average number of DCD DDLTs was 2.4 per day, regional imports were 7.3 per day, and national imports were 7.4 per day (Figure 4B-D).

The average number of LDLTs performed per weekday was 2 before March 15 (Figure 5A). After a rapid decline from March 15 to April 1, the average number of LDLTs plateaued at 1 throughout April. Throughout May to September, the average number of LDLTs increased slowly. After March 15, only five centers performed more than 1 LDLT (Figure 5B). Two of the centers were in states with fewer than four COVID-19 cases per day per 100,000 population. One of the centers was in a state with more than 32 COVID-19 cases per day per 100,000 population.

3.3 | Comparing observed to expected center-level numbers of LT waitlist events

Overall, from March 15 to April 30, the number of new listings observed was 11% fewer than expected (IRR = 0.84 0.89 0.93, Table 1), 21% fewer in May (IRR = 0.79 0.84), and as expected during June-August. Overall, the number of waitlist deaths was not different than expected for any period. The overall number of LDLTs observed were 49% lower than expected from March 15 to April 30 (IRR = 0.51 0.72) and 42% less than expected in May (IRR = 0.58 0.85). However, in June-August, the overall number of LDLTs observed was similar to expected. Overall, the number of DDLTs observed was 9% lower than expected during March 15-April 30 (IRR = 0.91 0.97), 13% higher in May (IRR = 1.05 1.21), 15% higher in June (IRR = 1.15 1.23), 14% higher in July (IRR = 1.06 1.14), and 13% higher in August (IRR = 1.05 1.13).

From March 15 to April 30, among centers in states with “medium” COVID-19 incidence, there were 21% fewer new waitlist registrants than expected (IRR = 0.69 0.79 0.90). The decrease in new listings for centers in states with “very high” COVID-19 burden was more severe, with 33% fewer new listings than expected.
There were 59% more waitlist deaths than expected among centers in states with "very high" COVID-19 rates (IRR = 1.09 1.59 2.32). Among centers in states with "low" incidence, there were 84% fewer LDLT than expected (IRR = 0.07 0.16 0.38) and 65% fewer for "very high" incidence states (IRR = 0.13 0.35 0.94).

From March 15 to April 30, the observed number of DDLTs was also 41% less than expected at centers in states with "high" COVID-19 burden (IRR = 0.44 0.59 0.79) (Table 1) and 34% at centers in states with "very high" COVID-19 incidence (IRR = 0.50 0.66 0.80). The IRRs were both statistically significantly less than the IRRs for centers in states with "low" COVID-19 rates. The decline in DDLT was greatest among patients with MELD less than 20 (eg, for MELD 15-19, 92 observed versus 142.4 expected, −35.4%, p < .001) (Table 2), and patients who received exception points (67 observed versus 154.5 expected, p < .001). Among patients with MELD 25-29, there were 21.1% (144 observed versus 118.9 expected, p < .001), and for MELD 30-34 there were 50.4% (154 observed versus 102.4 expected, p < .001) more DDLT observed than expected.

In May, centers in all categories of COVID-19 incidence had 19-25% fewer than expected new listings (IRR_{low} = 0.75 0.84 0.94; IRR_{med} = 0.69 0.78 0.88; IRR_{high} = 0.44 0.75 0.88; IRR_{veryhigh} = 0.70 0.81 0.93) (Table 1). Among centers in states with "very high" COVID-19 burden, there were 68% fewer LDLT than expected (IRR = 0.13 0.32 0.78).

The observed number of DDLTs was 18% more than expected at centers in states with "low" COVID-19 burden (IRR = 1.05 1.18 1.34). Centers in states with "low" COVID-19 incidence continued to be more engaged in DCD DDLT with two times more than expected (IRR = 1.08 1.52 2.12).

In June, centers across all categories had observed rates similar to expected for new listings, waitlist death, and LDLT (Table 1). The observed number of DDLTs was 24% more than expected at centers in states with "low" COVID-19 burden (IRR = 1.05 1.24 1.49). Centers in states with "low" COVID-19 incidence continued to be more engaged in DCD DDLT with two times more than expected.

(IRR = 1.09 1.59 2.32) which was also a statistically significantly stronger decrease than for centers in states with "low" COVID-19 burden. There were 59% more waitlist deaths than expected among centers in states with "very high" COVID-19 rates (IRR = 1.09 1.59 2.32). Among centers in states with "low" incidence, there were 84% fewer LDLT than expected (IRR = 0.07 0.16 0.38) and 65% fewer for "very high" incidence states (IRR = 0.13 0.35 0.94).

From March 15 to April 30, the observed number of DDLTs was also 41% less than expected at centers in states with "high" COVID-19 burden (IRR = 0.44 0.59 0.79) (Table 1) and 34% at centers in states with "very high" COVID-19 incidence (IRR = 0.50 0.66 0.80). The IRRs were both statistically significantly less than the IRRs for centers in states with "low" COVID-19 rates. The decline in DDLT was greatest among patients with MELD less than 20 (eg, for MELD 15-19, 92 observed versus 142.4 expected, −35.4%, p < .001) (Table 2), and patients who received exception points (67 observed versus 154.5 expected, p < .001). Among patients with MELD 25-29, there were 21.1% (144 observed versus 118.9 expected, p < .001), and for MELD 30-34 there were 50.4% (154 observed versus 102.4 expected, p < .001) more DDLT observed than expected.

In May, centers in all categories of COVID-19 incidence had 19-25% fewer than expected new listings (IRR_{low} = 0.75 0.84 0.94; IRR_{med} = 0.69 0.78 0.88; IRR_{high} = 0.44 0.75 0.88; IRR_{veryhigh} = 0.70 0.81 0.93) (Table 1). Among centers in states with "very high" COVID-19 burden, there were 68% fewer LDLT than expected (IRR = 0.13 0.32 0.78).

The observed number of DDLTs was 18% more than expected at centers in states with "low" COVID-19 burden (IRR = 1.05 1.18 1.34). Centers in states with "low" COVID-19 incidence continued to be more engaged in DCD DDLT with two times more than expected (IRR = 1.08 1.52 2.12).

In June, centers across all categories had observed rates similar to expected for new listings, waitlist death, and LDLT (Table 1). The observed number of DDLTs was 24% more than expected at centers in states with "low" COVID-19 burden (IRR = 1.05 1.24 1.49). Centers in states with "low" COVID-19 incidence continued to be more engaged in DCD DDLT with two times more than expected.
In July and August, the rates of most waitlist events were similar to expected across the incidence categories. Of note, the observed number of DDLT in July in "high" incidence states were 57% more than expected (IRR = 1.23 1.57 2.00) (Table 1). The observed number of DDLT in August in "high" incidence states were 26% more than expected (IRR = 1.06 1.26 1.49). The overall number of observed regional imports were higher than expected in May (IRR = 1.15 1.30 1.49) and June (IRR = 1.15 1.30 1.49), but as expected by August (Table 1). While there were 15% more observed regional imports to states with "low" COVID-19 burden than expected during March 15-April 30 (IRR = 1.02 1.15 1.30), there were 71% fewer (IRR = 0.13 0.29 0.43) observed regional imports to centers in states with "very high" COVID-19 rates. In June, observed regional imports were still more than expected for centers in "low" COVID-19 burden states (IRR = 1.50 1.80 2.17) and similar to that expected (IRR = 0.55 0.89 1.49) in centers in "very high" burden states. Additionally, the IRRs for medium, high, and very high COVID-19 levels in May and June were each statistically significantly different from the centers in states with low COVID-19 burden. The overall observed number of national imports was 3.5 times higher than expected during March 15-April 30 (IRR = 3.13 3.52 3.99), 4.7 times higher in May (IRR = 4.11 4.66 5.29), and 4.7 times higher in June (IRR = 4.09 4.66 5.29). In July and August, national imports continued to be higher than expected across all incidence levels.

4 | DISCUSSION

In this national study of LT waitlist activity compared to pre-COVID-19 trends and stratified by COVID-19 incidence across five periods of the pandemic, we found the overall number of new listings, LDLT, and DDLT were vastly different than expected early in the pandemic. The early decreases in events also occurred differentially across COVID-19 incidence levels. Specifically, from March 15 to April 30, there was no change in new listings or DDLT in states with the lowest COVID-19 burden, but in states with the highest incidence, there were 33% fewer new listings than expected and 34% fewer DDLTs. The changes in DDLT occurred differently across MELD scores; there were 35.4% fewer DDLTs than expected for MELD 15-19 and 50.4% more DDLT than expected for MELD 30-34. Early in the pandemic, LDLTs were 65% fewer than expected in states with the highest burden. Importantly, while the overall number of waitlist deaths across all time periods was as expected, in the states with the highest COVID-19 incidence early in the pandemic, there was a 59% increase in deaths on the waitlist compared to expected. By August, waitlist outcomes were occurring at expected rates based on prepandemic averages, except for DDLT which was occurring at 13% more than expected across all incidence levels. While early in the pandemic the COVID-affected areas had major changes to their transplant practice, later in the pandemic the new COVID-affected areas did not seem to be affected to the same extent. Perhaps these results speak to the adaptability of the transplant community in addressing the pandemic and applying new knowledge to patient care, so our colleagues in Florida and Arizona did not require the same extreme reactions as earlier states, such as New York.

Our findings confirm the anecdotal reports from our recent national survey of transplant centers and are consistent with a prior...
COVID-19 era study. The survey described restrictions to DDLT reported by 73.3% of centers. The overall decrease in DDLT and differential reduction of DDLT among states of higher incidence rates of COVID-19 is likely reflective of lower hospital capacity and healthcare resources. While decrease in LDLT among centers in states with high COVID-19 burden is likely representative of the 67.7% cessation of LDLT among LDLT programs reported in the survey (potentially from the dilemma of increased donor risk), the numbers in the other COVID-19 burden groups were likely too small to reach statistical significance. Additionally, our findings are also consistent with the report from Agopian et al that 39% of centers had a difference of greater than or equal to 6 DDLT during February-March between 2019 and 2020. Our study extends the Agopian study by estimating expected rates from 4 years of data instead of 3 months, by accounting for secular trends and center-level changes in waitlist population, and by providing inference through April 2020.

National societies have acknowledged the uncertainty among the LT community, and they have provided clinical guidance for LT centers across the world on maintaining care according to pre-COVID-19 clinical guidelines while considering minimizing SARS-COV-2 transmission (eg, personal protective equipment use, social distancing, telemedicine).

Our results show a striking increase in waitlist deaths in the states with the highest COVID-19 incidence in the earliest wave of the pandemic. There are several potential explanations. Our data do not include the cause of death, but some of these deaths may have been directly caused by COVID-19 infection and/or comorbidities. A study from China about patients with metabolic-associated fatty liver disease demonstrated a sixfold increased risk for severe COVID-19 in obese patients. However, according to the CDC, chronic liver disease has had few severe outcomes reported, so the risk for severe COVID-19 is not yet known. Furthermore, since transplant centers in these states were performing fewer transplants, patients with higher MELD scores may have been dying of their end-stage liver disease before they could be transplanted. Another possibility is that hospitals at full capacity with COVID-19 patients may not have been

---

**Figure 4** Counts of DDLTs per day, February 1-September 2, 2020, with LOWESS smooth. (A) DDLT decreased after March 15, increased April to mid-May, and plateaued back to baseline mid-May to September. (B) DCD DDLTs, (C) regional imports, and (D) national imports were stable. DCD, donation after circulatory death; DDLT, deceased donor liver transplant [Color figure can be viewed at wileyonlinelibrary.com]
able to admit the patients whom they would normally manage for decompensated liver disease.

Our model of observed versus expected must be interpreted in the context of the major policy change on February 4, 2020 to organ allocation based on the geographic distance between the recipient and deceased donor (“acuity circles”).27 Under acuity circles, organs are allocated based on distance from recovery hospital, replacing prior donor service areas and regions. The increase in national imports across all levels of statewide COVID-19 incidence, might reflect the impact of acuity circles rather than COVID-19 burden states, our results may in fact underestimate the true mortality impact of the epidemic in these states. Testing strategies and availability for SARS-CoV-2 have been changing since the beginning of the pandemic, 30,31 which may have also led to an underestimation of COVID-19 incidence. 32 However, misclassification of COVID-19 burden would be expected to bias our results toward the null.

In summary, these findings suggest that COVID-19 has impacted all aspects of LT, and a better understanding of COVID-19 may benefit this patient population. In states with the highest COVID-19 burden early on, there was a dramatic reduction in LDLT and increased mortality for LT candidates. Future research related to post-LT COVID-19 incidence and survival outcomes is needed.
### TABLE 1  Observed center-level events as a proportion of expected events, March 15-August 31, 2020

| COVID-19 incidence | New listings | Waitlist death | LDLT | DDLT | DCD | DDLT | Regional import | National import |
|---------------------|--------------|----------------|------|------|-----|------|-----------------|-----------------|
| March 15-April 30   |              |                |      |      |     |      |                 |                 |
| Overall             | 0.84         | 0.89           | 0.93 | 0.98 | 1.15| 1.35 | 0.37           | 0.51           |
| Low                 | 0.91         | 0.96           | 0.93 | 0.91 | 1.12| 1.37 | 0.07           | 0.16           |
| Medium              | 0.56         | 0.69           | 0.88 | 0.65 | 1.10| 1.86 | 0.00           | 0.35           |
| High                | 0.56         | 0.69           | 0.88 | 0.65 | 1.10| 1.86 | 0.00           | 0.35           |
| Very high           | 0.55         | 0.67           | 1.09 | 1.59| 2.32| 0.13 | 0.35           | 0.94           |
| May 1-May 31        |              |                |      |      |     |      |                 |                 |
| Overall             | 0.74         | 0.79           | 0.84 | 0.80 | 0.99| 1.22 | 0.39           | 0.58           |
| Low                 | 0.74         | 0.83           | 0.92 | 0.61 | 0.94| 1.46 | 0.30           | 0.92           |
| Medium              | 0.66         | 0.77           | 0.87 | 0.54 | 0.81| 1.23 | 0.28           | 0.58           |
| High                | 0.63         | 0.74           | 0.87 | 0.38 | 0.75| 1.50 | 0.43           | 0.77           |
| Very high           | 0.69         | 0.79           | 0.91 | 0.93 | 1.29| 1.80 | 0.13           | 0.32           |
| June 1-June 30      |              |                |      |      |     |      |                 |                 |
| Overall             | 0.92         | 0.97           | 1.03 | 0.80 | 1.00| 1.24 | 0.79           | 1.06           |
| Low                 | 0.89         | 1.03           | 1.19 | 0.69 | 1.21| 1.33 | 0.41           | 1.63           |
| Medium              | 0.90         | 0.98           | 1.06 | 0.79 | 1.05| 1.38 | 0.74           | 1.04           |
| High                | 0.78         | 0.90           | 1.05 | 0.37 | 0.67| 1.22 | 0.49           | 1.03           |
| Very high           | 0.81         | 1.00           | 1.24 | 0.58 | 1.07| 1.99 | 0.94           | 1.24           |
| July 1-July 31      |              |                |      |      |     |      |                 |                 |
| Overall             | 0.99         | 1.03           | 1.10 | 0.78 | 0.96| 1.20 | 0.90           | 1.18           |
| Low                 | 0.87         | 1.00           | 1.17 | 0.48 | 0.80| 1.33 | 0.63           | 1.12           |
| Medium              | 0.88         | 0.98           | 1.09 | 0.78 | 1.12| 1.63 | 0.74           | 1.10           |
| High                | 0.79         | 0.99           | 1.23 | 0.08 | 0.33| 1.34 | 0.20           | 1.43           |
| Very high           | 1.06         | 1.09           | 1.38 | 0.76 | 1.04| 1.43 | 0.84           | 1.36           |
| August 1-August 31  |              |                |      |      |     |      |                 |                 |
| Overall             | 0.91         | 0.96           | 1.02 | 0.71 | 0.88| 1.11 | 0.63           | 0.87           |
| Low                 | 0.77         | 0.97           | 1.23 | 0.40 | 0.83| 1.75 | 0.15           | 0.47           |
| Medium              | 0.78         | 0.92           | 1.07 | 0.38 | 0.70| 1.31 | 0.44           | 0.80           |
| High                | 0.75         | 0.88           | 1.03 | 0.54 | 0.98| 1.77 | 0.57           | 1.14           |
| Very high           | 0.92         | 0.99           | 1.07 | 0.69 | 0.92| 1.22 | 0.60           | 0.96           |

Note. COVID-19 incidence stratified based on cases per 100,000 population per day during the last week in March (for March 15-April 30) or during the last week of the prior month (for May and August). Bold denotes statistically significant IRRs; underline denotes IRRs that are significantly different from the IRR in states with the lowest per-capita COVID-19 cases.

Abbreviations: DCD, donation after circulatory death; DDLT, deceased donor liver transplant; LDLT, living donor liver transplant.

### ACKNOWLEDGMENTS

This research was made possible with generous support of the Ben-Dov family. This work was supported by grant number F32DK124941 (Boyarsky), T32AI007291 (Werbel), F32DK113719 (Jackson), F32DK117563 (Kernodle), K01KD101677 (Massie), and K23DK115908 (Garonzik-Wang) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH). This work was supported by grant number K24AI144954 (Segev) from the National Institute of Allergy and Infectious Diseases (NIAID). The analyses described here are the responsibility of the authors alone and do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the U.S. Government. The data reported here have been supplied by the Hennepin Healthcare Research Institute (HHRI) as the contractor for the Scientific Registry of Transplant Recipients (SRTR). The interpretation and reporting of these data are the responsibilities of the author(s) and in no way should be seen as an official policy of or interpretation by the SRTR or the U.S. Government.

### DISCLOSURE

The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.
TABLE 2 Characteristics of DDLT recipients by expected and observed counts from March 15 to April 30, 2020

| Category          | Observed | Expected | % change | p-value |
|-------------------|----------|----------|----------|---------|
| Overall           | 882      | 971.2    | -9.2     | <.01    |
| Age               |          |          |          |         |
| 0-11              | 33       | 36.8     | -10.3    |         |
| 12-17             | 8        | 8.9      | -10.1    |         |
| 18-29             | 24       | 29.4     | -18.4    |         |
| 30-39             | 78       | 76.2     | 2.4      | .7      |
| 40-49             | 133      | 130.1    | 2.2      |         |
| 50-59             | 272      | 283.9    | -4.2     |         |
| 60-69             | 296      | 339.5    | -12.8    |         |
| 70+               | 38       | 47.8     | -20.5    |         |
| Prior transplant  |          |          |          |         |
| No                | 839      | 925.7    | -9.4     | .4      |
| Yes               | 43       | 38.1     | 12.9     |         |
| Race/Ethnicity    |          |          |          |         |
| White             | 613      | 668.7    | -8.3     |         |
| Black             | 62       | 74.8     | -17.1    |         |
| Hispanic          | 158      | 160.1    | -1.3     | .9      |
| Asian             | 34       | 37.6     | -9.6     |         |
| Other             | 15       | 18.8     | -20.2    |         |
| Insurance payor type |       |          |          |         |
| Private           | 453      | 482.4    | -6.1     |         |
| Medicaid          | 169      | 175.0    | -3.4     |         |
| Medicare          | 222      | 239.6    | -7.3     | .4      |
| Other public      | 13       | 24.1     | -46.1    |         |
| Other             | 22       | 24.7     | -10.9    |         |
| Sex               |          |          |          |         |
| Male              | 570      | 618.2    | -7.8     | .9      |
| Female            | 312      | 347.5    | -10.2    |         |
| Status            |          |          |          |         |
| MELD <15          | 101      | 159.8    | -36.8    |         |
| MELD 15-19        | 92       | 142.4    | -35.4    |         |
| MELD 20-24        | 126      | 146.4    | -13.9    | <.001   |
| MELD 25-29        | 144      | 118.9    | 21.1     |         |
| MELD 30-34        | 154      | 102.4    | 50.4     |         |
| MELD 35+          | 162      | 166.2    | -2.5     |         |
| Status 1          | 36       | 40.0     | -10.0    |         |
| Exception         | 67       | 154.5    | -56.6    |         |

Note. The overall observed number was 9.2% less than expected. Abbreviation: MELD, Model for End Stage Liver Disease.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the SRTR. Restrictions apply to the availability of these data, which were used under license for this study. Data are available at https://www.srtr.org/ with the permission of SRTR.

ORCID
Alexandra T. Strauss  https://orcid.org/0000-0001-6313-7221
Brian J. Boyarsky  https://orcid.org/0000-0001-6902-9854
William Werbel  https://orcid.org/0000-0003-2943-5895
Christine M. Durand  https://orcid.org/0000-0003-2605-9257
Robin K. Avery  https://orcid.org/0000-0001-7692-3619
Kyle R. Jackson  https://orcid.org/0000-0002-8135-5377
Amber B. Kernodle  https://orcid.org/0000-0002-6459-5280
Jon Snyder  https://orcid.org/0000-0001-7974-8940
Dorry L. Segev  https://orcid.org/0000-0002-1924-4801
Allan B. Massie  https://orcid.org/0000-0002-5288-5125

REFERENCES
1. Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsuie P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;105924.
2. del Rio C, Malani PN. 2019 Novel coronavirus—important information for clinicians. JAMA. 2020;323(11):1039–1040.
3. Truog RD, Mitchell C, Daley GQ. The toughest triage—allocating ventilators in a pandemic. N Engl J Med. 2020;382(21):1973–1975.
4. Cavallo JJ, Donoho DA, Forman HP. Hospital capacity and operations in the coronavirus disease 2019 (COVID-19) pandemic—planning for the nth patient. JAMA Health Forum. 2020;1(3):e200345.
5. Qin J, Wang H, Qin X, et al. Perioperative presentation of COVID-19 disease in a liver transplant recipient. Hepatol. 2020. https://doi.org/10.1002/hep.31257.
6. Michaels MG, La Hoz RM, Danziger-Isakov L, et al. Coronavirus disease-2019: Implications of emerging infections for transplantation. Am J Transplant. 2020. https://doi.org/10.1111/ajt.15832.
7. CDC COVID-19 Response Team. MMWR: Severe outcomes among patients with coronavirus disease 2019 (COVID-19) — United States, February 12–March 16, 2020. 2020. http://www.cdc.gov/mmwr/;2020/105924.
8. Hammami MB, Garibaldi B, Shah P, et al. Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: A case report. Am J Transplant. 2020. https://doi.org/10.1111/ajt.15909.
9. Huang J-F, Zheng KI, George J, et al. Fatal outcome in a liver transplant recipient. Am J Transplant. 2020. https://doi.org/10.1111/ajt.15985.
10. Gandolfini I, Delsante M, Fiaccadori E, et al. COVID-19 in kidney transplant recipients. Am J Transplant. 2020. https://doi.org/10.1111/ajt.15909.
11. Fishman JA, Grossi PA. Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve. Am J Transplant. 2020. https://doi.org/10.1111/ajt.15891.
12. Boyarsky BJ, Chiang TP-Y, Werbel WA, et al. Early impact of COVID-19 on transplant center practices and policies in the United States. Am J Transplant. 2020. https://doi.org/10.1111/ajt.15915.
13. US Census Bureau. State Population Change: 2010 to 2018. 2020. https://www.census.gov/library/visualizations/2018/comm/population-change-2010-2018.html. Accessed March 25, 2020.
14. The COVID Tracking Project. The Atlantic. https://covidtracking.com/. Accessed March 25, 2020.
15. Massie AB, Kucikra LM, Segev DL. Big data in organ transplantation: registries and administrative claims. Am J Transplant. 2014;14(8):1723–1730.
16. Louis TA, Zeger SL. Effective communication of standard errors and confidence intervals. Biostatistics. 2009;10(1):1–2.
17. Fix OK, Hameed B, Fontana RJ, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. *Hepatol*. 2020. https://doi.org/10.1002/hep.31281

18. Communities CDC, Schools Workplaces, Events. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/community/organizations/cleaning-disinfection.html. Accessed June 3, 2020.

19. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*. 2020. https://doi.org/10.1001/jama.2020.4907

20. Moroni F, Gramegna M, Ajello S, et al. Collateral damage: Medical care avoidance behavior among patients with myocardial infarction during the COVID-19 pandemic. *JACC: Case Reports*. April 2020. https://doi.org/10.1016/j.jaccr.2020.04.010

21. Emanuel EJ, Persad G, Upshur R, et al. Fair allocation of scarce medical resources in the time of Covid-19. *N Engl J Med*. 2020. https://doi.org/10.1056/NEJMsb2005114

22. Agopian V, Verna E, Goldberg D. Changes in liver transplant center practice in response to COVID-19: Unmasking dramatic center-level variability. *Liver Transpl*. 2020. https://doi.org/10.1002/lt.25789

23. Boettler T, Newsome PN, Mondelli MU, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. *JHEP Rep*. 2020;2(3):100113.

24. Saigal S, Gupta S, Sudhindran S, et al. Liver transplantation and COVID-19 (Coronavirus) infection: guidelines of the liver transplant Society of India (LTSI). *Hepatol Int*. 2020. https://doi.org/10.1007/s12072-020-10041-1

25. Zheng KI, Gao F, Wang X-B, et al. Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. *Metabolism*. 2020;108:154244.

26. CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - United States, February 12-March 28, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(13):382–386.

27. UNOS. System notice: Liver and intestinal organ distribution based on acuity circles implemented Feb. 4. https://unos.org/news/system-implementation-notice-liver-and-intestinal-organ-distribution-based-on-acuity-circles-implemented-feb-4/. Accessed June 3, 2020.

28. Mogul D, Perito ER, Wood N, et al. Impact of acuity circles on outcomes for pediatric liver transplant candidates. *Transplantation*. 2019. https://doi.org/10.1097/TP.0000000000003079

29. Bertsimas D, Papalexopoulos T, Trichakis N, Wang Y, Hirose R, Vageli PA. Balancing efficiency and fairness in liver transplant access: tradeoff curves for the assessment of organ distribution policies. *Transplantation*. 2020;104(5):981–987.

30. Gronvall G, Connell N, Kobokovich A, et al. Developing a National Strategy for Serology (Antibody Testing) in the United States. Baltimore, MD: Johns Hopkins University; 2020.

31. Cheng MP, Papenburg J, Desjardins M, et al. Diagnostic testing for severe acute respiratory syndrome–related coronavirus-2: A narrative review. *Ann Intern Med*. 2020. https://www.acpjournals.org/doi/abs/10.7326/m20-1301

32. Omori R, Mizumoto K, Chowell G. Changes in testing rates could mask the novel coronavirus disease (COVID-19) growth rate. *Int J Infect Dis*. 2020;94:116–118.

How to cite this article: Strauss AT, Boyarsky BJ, Garonzik-Wang JM, et al. Liver transplantation in the United States during the COVID-19 pandemic: National and center-level responses. *Am J Transplant*. 2021;21:1838–1847. https://doi.org/10.1111/ajt.16373